curf@clemson.edu's Latest Posts
11/22/24
Clemson Inventors Honored with 2024 InnoVision Awards
The 2024 InnoVision Awards recognized groundbreaking innovations from two companies with ties to the Clemson University Research Foundation, highlighting the collaborative efforts between industry and academia. MyUI.ai, winner in the Community Service category, leverages technology originally developed at Clemson University by Dr. Julian Brinkley, a faculty entrepreneur and the company’s Founder & CEO. This advanced artificial intelligence technology, developed by…
curf@clemson.edu
10/30/24
Clemson, NSF Hub to Advance Commercialization of University Research
Link to Original Story: https://news.clemson.edu/clemson-nsf-hub-to-advance-commercialization-of-university-research/ Clemson University has joined a hub of Southeast universities tasked by the National Science Foundation (NSF) to help nurture the commercialization of innovation with a new $15 million investment. The NSF Southeast I-Corps Hub of eight institutions in four states will work to identify business development opportunities for new technologies, prepare inventors for commercial success and… curf@clemson.edu
10/09/24
Two Clemson Start-Ups Named 2024 InnoVision Awards Finalists
Two Clemson start-ups have been selected as finalists for the InnoVision Awards! These finalists were selected as distinguished South Carolina businesses who are setting new benchmarks in innovation and technology. Dr. Julian Brinkley’s technology, MyUI.AI, has been nominated for the Community Service Award. The InnoVision Community Service Award recognizes an organization for an innovation that improves the quality of life… curf@clemson.edu
05/01/24
Positioning CURF for Continued Success
Dear Colleagues, Last month, our Board of Directors met for a mid-year update to hear from a wide range of guest speakers from the research community. Our office continues to work diligently to be a model for research collaboration, technology maturation, commercialization, and entrepreneurial support. In addition, we continue to develop our resource planning to scale our service offerings to… curf@clemson.edu
05/01/24
Nectero Medical begins Phase II/III Clinical Trials
Nectero Medical is a clinical-stage biotech startup that is developing novel therapies to address the challenges of treating aneurysmal disease. The company’s focus is on improving outcomes for patients with abdominal aortic aneurysms (AAA), a condition that affects over 1 million Americans. The foundation of Nectero Medical’s approach is a patented compound developed by and licensed from Dr. Naren Vyavahare’s… curf@clemson.edu